| | |
ASPsiRNA information |
siRNA Id: | aspsirna3178
|
siRNA Name: | mi306.12
|
Mismatch information |
Wild siRNA (As strand 3'->5'): | AACGGUCCAAUGUCGACGAGAA
|
ASP-siRNA (As strand 3'->5'): | AACGGUCCAACGUCGACGAGAA
|
Mismatch position in siRNA: | C12U |
Gene Information |
Gene Name | Hungtintin (HTT) |
Target Sequence (5'->3'): | NA
|
Wild allele (5'->3'): | UUGCCAGGUUACAGCUGCUCUU
|
Mutant allele (5'->3'): | UUGCCAGGUUGCAGCUGCUCUU
|
Position of siRNA on target gene: | NA
|
Respective Gene/Protein Resources |
GenBank Accession: | NM_002111.7 |
Cytogenic location: | 4p16.3 |
Chromosomal coordinates: | 4:3,076,407-3,245,686 |
UniProt ID: | P42858 |
HUGO ID: | 4851 |
Reference SNp(RefSNP): | rs362306 |
Disease/Mutation information |
Target Mutation: | rs362306
|
Matation type/variant: | microsatellite
|
Mutation at gene level: | NG_009378.1:g.5197CAG(36_39)
|
Pathogenic status of mutation: | Pathogenic
|
Disease: | Huntington disease (HD) |
Clinical Resources |
ClinVar ID: | 31916 |
KEGG disease ID: | H00059 |
OMIM ID: | 143100 |
COSMIC: | HTT |
DECIPHER: | HTT |
GeneTests: | HTT |
ASP siRNA details |
Mutant allele (5'->3'): | UUGCCAGGUUGCAGCUGCUCUU
|
ASP-siRNA (As strand 3'->5'): | AACGGUCCAACGUCGACGAGAA
|
Percentage efficacy of ASP-siRNA for mutant allele: | 90
|
Wild allele (5'->3'): | UUGCCAGGUUACAGCUGCUCUU
|
ASP-siRNA (As strand 3'->5'): | AACGGUCCAACGUCGACGAGAA
|
Percentage efficacy of ASP-siRNA for wild allele: | 26
|
Relative difference: | 64
|
Wild siRNA details |
Wild allele (5'->3'): | UUGCCAGGUUACAGCUGCUCUU
|
Wild siRNA (As strand 3'->5'): | AACGGUCCAAUGUCGACGAGAA
|
Percentage efficacy of wild siRNA for wild allele: | 45
|
Wild allele (5'->3'): | UUGCCAGGUUACAGCUGCUCUU
|
ASP-siRNA (As strand 3'->5'): | AACGGUCCAACGUCGACGAGAA
|
Percentage efficacy of Wild sirna for mutant allele: | 57
|
Relative difference : | -12
|
General information |
Mismatch incorporated in siRNA/Target: | siRNA |
Cell-line used: | Transgenic mouse model |
Experimental technique used: | qRT-PCR |
Transfection method: | Lipofectamine 2000 |
siRNA expression method: | Invitrogen |
Post-transfection duration: | 3 weeks |
Concentration used: | 40 nM |
Reference: | 25849618 |
Delivery method: | AAV2/1 allele- specific virus |
'Article title: | Artificial miRNAs Targeting Mutant Huntingtin Show Preferential Silencing In Vitro and In Vivo |
'Authors: | Monteys AM,Wilson MJ,Boudreau RL,Spengler RM,Davidson BL |
'Journal Reference: | Mol Ther Nucleic Acids. 2015 Apr 7;4:e234. doi: 10.1038/mtna.2015.7 |
'